16 results
424B5
SLNO
Soleno Therapeutics Inc
2 May 24
Prospectus supplement for primary offering
4:04pm
of the obese state.
DCCR’s unique mode of action with targets in the brain, pancreas and fat tissue has the potential to broadly impact complex diseases like … and perpetuation of the obese state.
DCCR’s unique mode of action with targets in the brain, pancreas and fat tissue has the potential to broadly
S-3ASR
SLNO
Soleno Therapeutics Inc
2 Jan 24
Automatic shelf registration
4:06pm
of the obese state.
DCCR’s unique mode of action with targets in the brain, pancreas and fat tissue has the potential to broadly impact complex
424B5
SLNO
Soleno Therapeutics Inc
29 Sep 23
Prospectus supplement for primary offering
4:51pm
and the establishment and perpetuation of the obese state.
DCCR’s unique mode of action with targets in the brain, pancreas and fat tissue has the potential
424B5
uq8s5d
27 Sep 23
Prospectus supplement for primary offering
5:26pm
424B5
bo3 wyqpalmpd16opo8w
30 Mar 22
Prospectus supplement for primary offering
5:21pm
424B5
k7x6gq jx
28 Mar 22
Prospectus supplement for primary offering
4:53pm
424B5
tww61l blu
16 Jul 21
Prospectus supplement for primary offering
4:07pm
8-K
EX-99.1
l4l4hqp08
15 Nov 18
Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2018
4:02pm
S-1/A
l99u54lyrlcc
1 Jul 14
IPO registration (amended)
12:00am
- Prev
- 1
- Next